 |
|
Cerebrospinal Fluid Tau and  -Amyloid
How Well Do These Biomarkers Reflect Autopsy-Confirmed Dementia Diagnoses?
Christopher M. Clark, MD;
Sharon Xie, PhD;
Jesse Chittams, MS;
Douglas Ewbank, PhD;
Elaine Peskind, MD;
Douglas Galasko, MD;
John C. Morris, MD;
Daniel W. McKeel, Jr, MD;
Martin Farlow, MD;
Sharon L. Weitlauf, RN;
Joseph Quinn, MD;
Jeffrey Kaye, MD;
David Knopman, MD;
Hiroyuki Arai, MD, PhD;
Rachelle S. Doody, MD, PhD;
Charles DeCarli, MD;
Susan Leight, BS;
Virginia M.-Y. Lee, PhD;
John Q. Trojanowski, MD, PhD
Arch Neurol. 2003;60:1696-1702.
Background Tau and  -amyloid (A) are proposed diagnostic biomarkers for Alzheimer disease (AD). Previous studies report their relationship to clinical diagnoses of AD and other dementias. To understand their value as predictors of disease-specific patholody, levels determined during life must be correlated with definitive diagnoses in mixed dementia groups and cognitively normal subjects.
Objectives To correlate antemortem cerebrospinal fluid (CSF) tau and A levels with definitive dementia diagnosis in a diverse group of patients; to calculate statistics for CSF tau and A.
Design Prospective study.
Setting Ten clinics experienced in the diagnosis of neurodegenerative dementias.
Patients One hundred six patients with dementia and 4 cognitively normal subjects with a definitive diagnosis, and 69 clinically diagnosed cognitively normal subjects.
Main Outcome Measures Correlation of CSF tau and A with final diagnosis.
Results Mean tau level was 612 pg/mL for the 74 patients with AD, 272 pg/mL for 10 patients with frontal dementia, 282 pg/mL for 3 patients with dementia with Lewy bodies, and 140 pg/mL for 73 cognitively normal control subjects. Tau was less than 334 pg/mL for 20 patients with AD. A42 was reduced in patients with AD (61 fmol/mL) compared with patients with frontal dementia (133 fmol/mL) and control subjects (109 fmol/mL), but not compared with patients with dementia with Lewy bodies (14 fmol/mL) or prion disease (60 fmol/mL).
Conclusions Elevated CSF tau levels are associated with AD pathology and can help discriminate AD from other dementing disorders. However, some patients with AD have a level less than the mean ± 2 SDs of the cognitively normal cohort.
From the Departments of Neurology (Dr Clark) and Pathology and Laboratory Medicine (Drs Lee and Trojanowski and Ms Leight), Center for Neurodegenerative Disease Research (Drs Lee and Trojanowski and Ms Leight), Alzheimer's Disease Center (Drs Clark, Xie, Ewbank, and Trojanowski), Institute on Aging (Drs Clark and Trojanowski), Center for Clinical Epidemiology and Biostatistics (Dr Xie and Mr Chittams), and Population Studies Center (Dr Ewbank), University of Pennsylvania, Philadelphia; Department of Psychiatry and Behavioral Sciences and Alzheimer's Disease Research Center, University of Washington, Seattle (Dr Peskind); Department of Neurology and Alzheimer's Disease Research Center, University of California at San Diego (Dr Galasko); Departments of Neurology (Dr Morris) and Pathology (Drs Morris and McKeel) and Alzheimer's Disease Research Center (Drs Morris and McKeel), Washington University, St Louis, Mo; Department of Neurology and Alzheimer's Disease Center, Indiana University, Indianapolis (Dr Farlow and Ms Weitlauf); Department of Neurology and Alzheimer's Disease Research Center, Oregon Health Sciences University, Portland (Drs Quinn and Kaye); Department of Neurology, Mayo Clinic, Rochester, Minn (Dr Knopman); Department of Geriatric Medicine, Tohoku University, Sendai, Japan (Dr Arai); Department of Neurology and Alzheimer's Disease Research Center, Baylor College of Medicine, Houston, Tex (Dr Doody); and Department of Neurology, Kansas University, Kansas City (Dr DeCarli).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
CSF phosphorylated tau in the diagnosis and prognosis of mild cognitive impairment and Alzheimer's disease: a meta-analysis of 51 studies
Mitchell
J. Neurol. Neurosurg. Psychiatry 2009;80:966-975.
ABSTRACT
| FULL TEXT
MRI and CSF biomarkers in normal, MCI, and AD subjects: Diagnostic discrimination and cognitive correlations
Vemuri et al.
Neurology 2009;73:287-293.
ABSTRACT
| FULL TEXT
MRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change
Vemuri et al.
Neurology 2009;73:294-301.
ABSTRACT
| FULL TEXT
Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease
Jack et al.
Brain 2009;132:1355-1365.
ABSTRACT
| FULL TEXT
MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers
Schuff et al.
Brain 2009;132:1067-1077.
ABSTRACT
| FULL TEXT
CSF biomarkers in relationship to cognitive profiles in Alzheimer disease
van der Vlies et al.
Neurology 2009;72:1056-1061.
ABSTRACT
| FULL TEXT
Cerebrospinal Fluid {beta}-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Tapiola et al.
Arch Neurol 2009;66:382-389.
ABSTRACT
| FULL TEXT
CSF biomarkers in frontotemporal lobar degeneration with known pathology
Bian et al.
Neurology 2008;70:1827-1835.
ABSTRACT
| FULL TEXT
CSF tau/A{beta}42 ratio for increased risk of mild cognitive impairment: A follow-up study
Li et al.
Neurology 2007;69:631-639.
ABSTRACT
| FULL TEXT
Pittsburgh Compound B Retention and Verification of Amyloid Deposition
Holtzman
Arch Neurol 2007;64:315-316.
FULL TEXT
Cerebrospinal Fluid Amyloid {beta}42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia.
de Jong et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2006;61:755-758.
ABSTRACT
| FULL TEXT
From The Cover: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease
Georganopoulou et al.
Proc. Natl. Acad. Sci. USA 2005;102:2273-2276.
ABSTRACT
| FULL TEXT
|
